Literature DB >> 7630142

Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas.

S Moldovan1, A Atiya, T E Adrian, R M Kleinman, K Lloyd, K Olthoff, D Imagawa, L Shevlin, D Coy, J Walsh.   

Abstract

Recently five somatostatin receptor subtypes (SSTR) have been cloned, allowing the development of highly specific selective agonists for these SSTR. The present study was undertaken to determine which SSTR is responsible for the inhibitory effect of somatostatin on islet hormone secretion. Single-pass perfusion of four agonists was performed in pancreata obtained from four cadaveric organ donors using a modified Krebs-media with 3.9 mM glucose. Sequential 10-min specific receptor agonist infusions (5 ng/ml) of DC32-87 (SSTR2), DC25-12 (SSTR3), DC32-97 (SSTR3), or DC32-92 (SSTR5) were performed in random order separated by 10-min basal periods. Infusion of SSTR2 agonist into the isolated perfused human pancreas resulted in a significant inhibition of insulin and C-peptide secretion (insulin = -1468 +/- 480 pM, P < 0.05, and C-peptide = -2328 +/- 437 pM, P < 0.05) but not islet amyloid polypeptide or somatostatin. These results suggest that the inhibitory effect of somatostatin on B-cell secretion is mediated through the subtype-2 receptor within the human islet.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7630142     DOI: 10.1006/jsre.1995.1136

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  [Antidotes in clinical toxicology].

Authors:  K Hruby
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-08-08       Impact factor: 0.840

2.  Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Authors:  I Shimon; J E Taylor; J Z Dong; R A Bitonte; S Kim; B Morgan; D H Coy; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 3.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 4.  Proton pump inhibitors: impact on glucose metabolism.

Authors:  Diana Boj-Carceller
Journal:  Endocrine       Date:  2012-08-12       Impact factor: 3.633

5.  Intraislet somatostatin inhibits insulin (via a subtype-2 somatostatin receptor) but not islet amyloid polypeptide secretion in the isolated perfused human pancreas.

Authors:  A W Atiya; S Moldovan; T E Adrian; D Coy; J Walsh; F C Brunicardi
Journal:  J Gastrointest Surg       Date:  1997 May-Jun       Impact factor: 3.452

Review 6.  Pathophysiological Role of Genetic Factors Associated With Gestational Diabetes Mellitus.

Authors:  B Ortega-Contreras; A Armella; J Appel; D Mennickent; J Araya; M González; E Castro; A M Obregón; L Lamperti; J Gutiérrez; E Guzmán-Gutiérrez
Journal:  Front Physiol       Date:  2022-04-04       Impact factor: 4.755

7.  Association of SSTR2 polymorphisms and glucose homeostasis phenotypes: the Insulin Resistance Atherosclerosis Family Study.

Authors:  Beth S Sutton; Nicholette D Palmer; Carl D Langefeld; Bingzhong Xue; Alexandria Proctor; Julie T Ziegler; Steven M Haffner; Jill M Norris; Donald W Bowden
Journal:  Diabetes       Date:  2009-03-26       Impact factor: 9.461

8.  Radioiodinated naphthylalanine derivatives targeting pancreatic beta cells in normal and nonobese diabetic mice.

Authors:  John K Amartey; Yufei Shi; Ibrahim Al-Jammaz; Celestina Esguerra; Basem Al-Otaibi; Futwan Al-Mohanna
Journal:  Exp Diabetes Res       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.